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Background: The disappointing clinical failures of five topical vaginal microbicides have provided new insights into
factors that impact microbicide safety and efficacy. Specifically, the greater risk for human immunodeficiency virus
type 1 (HIV-1) acquisition associated with multiple uses of a nonoxynol-9 (N-9)-containing product has highlighted
the importance of application frequency as a variable during pre-clinical microbicide development, particularly in
animal model studies.
Methods: To evaluate an association between application frequency and N-9 toxicity, experiments were performed
using a mouse model of cervicovaginal microbicide safety. In this model system, changes in cervical and vaginal
epithelial integrity, cytokine release, and immune cell infiltration were assessed after single and multiple exposures
to N-9.
Results: After the initial application of N-9 (aqueous, 1%), considerable damage to the cervical epithelium (but not
the vaginal epithelium) was observed as early as 10 min post-exposure and up to 8 h post-exposure. Subsequent
daily exposures (up to 4 days) were characterized by diminished cervical toxicity relative to single exposures of like
duration. Levels of pro-inflammatory cytokines released into the cervicovaginal lumen and the degree of
CD14-positive immune cell infiltration proximal to the cervical epithelium were also dependent on the number of
N-9 exposures.
Conclusions: Rather than causing cumulative cervical epithelial damage, repeated applications of N-9 were
characterized by decreased sensitivity to N-9-associated toxicity and lower levels of immune cell recruitment. These
results provide new insights into the failure of N-9-based microbicides and illustrate the importance of considering
multiple exposure protocols in pre-clinical microbicide development strategies.
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The global human immunodeficiency virus type 1 (HIV-1)
epidemic currently includes approximately 33 million
HIV-1-infected people worldwide, with a particularly high
incidence of infection (~23 million individuals) in Sub-
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reproduction in any medium, provided the or30 years ago, the face of this global epidemic has changed
dramatically, with heterosexual intercourse now consi-
dered the predominant route for the spread of the virus
[1]. As a result, women are at much greater risk for ac-
quiring HIV-1 and have a much greater need for methods
that effectively reduce or eliminate the risk of infection
during sexual intercourse. Although condoms (male and
female) are highly effective barrier methods, they are not
female-controlled and are unlikely to be used with great
adherence in developing countries. To answer the critical
need for effective female-controlled methods of protec-
tion, continued efforts are being directed toward the de-
velopment of microbicides. A microbicide is a chemicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or reduce the risk of HIV-1 transmission. Efforts to de-
velop topical vaginal microbicides have resulted in the ad-
vancement of many candidate microbicide compounds
through pre-clinical studies and clinical trials of both safe-
ty and efficacy [2-4].
Unfortunately, clinical trials involving the microbicides
COL-1492 (nonoxynol-9 or N-9), Savvy (C31G), Usher-
cell (cellulose sulfate), Carraguard (carrageenan), and PRO
2000 [5-7] failed to demonstrate any product efficacy des-
pite promising activities in pre-clinical studies and appa-
rently acceptable levels of safety in early clinical studies.
The results of these failed trials emphasized the urgent
need for more stringent pre-clinical protocols, with em-
phasis on microbicide safety and the use of non-human
primate models to evaluate the efficacy and safety of po-
tential microbicides [8].
The clear need for more thorough pre-clinical evalua-
tions is particularly apparent in retrospective analyses of
the development of N-9 as a microbicide [9]. Pre-clinical
assessments of N-9 failed to predict the inability of N-9 to
inhibit HIV-1 transmission and the adverse effects of N-9
exposure on the risk of infection. Early in vitro studies of
N-9, which has been widely used as a spermicidal agent
for more than 40 years [9], yielded promising results,
demonstrating that N-9 possessed broad-spectrum activity
against several sexually transmitted disease (STD) patho-
gens, including Chlamydia trachomatis, Neisseria gonor-
rhoeae, herpes simplex virus type 2 (HSV-2), and HIV-1
[10-18]. The widespread and apparently safe use of N-9 as
a human contraceptive agent further supported the de-
velopment of this compound as a topical microbicide. As
a consequence, N-9 was advanced into human clinical
trials. However, the final phase 2/3 clinical trial of N-9
(formulated as COL-1492 with 52.5 mg N-9 per treatment
dose) demonstrated that high frequency use of this pro-
duct was associated with an almost 2-fold greater risk of
HIV-1 acquisition [5]. Increased HIV-1 infection after N-9
application, in hindsight, has been attributed to the dis-
ruption of the cervicovaginal epithelial barrier as well as
inflammation and irritation associated with N-9 applica-
tion [9,19-22]. While these findings ended the further de-
velopment of N-9 as a microbicide, they also raised new
questions about mechanisms by which potential topical
microbicides can fail.
The apparent association between N-9 application fre-
quency and increased risk of HIV-1 infection prompted
an expansion of our previous N-9 toxicity studies invol-
ving a Swiss Webster mouse model of cervicovaginal
toxicity. The value of this model system was demons-
trated in investigations that reiterated the clinical toxi-
city of N-9 (after a single application) and paralleled
indications of irritation associated with topical applica-
tion of 1.7% C31G [19,23,24]. Furthermore, mouse modelexperiments involving topical vaginal application of N-9
clearly demonstrated that (i) N-9-associated tissue damage
was greatest approximately two to four hours post-appli-
cation, (ii) epithelial damage was limited to the cervix, and
(iii) repair and regeneration of cervical epithelial tissues
was essentially complete 24 h after a single application of
N-9 [19].
The present studies were conducted using the mouse
model of microbicide toxicity to examine the effects
of multiple daily exposures to N-9. These experiments
were designed to provide a comprehensive assessment
of changes in cervicovaginal integrity with respect to
post-application exposure duration and the number of
topical applications of N-9. The results of these investiga-
tions indicated that (i) multiple exposures to N-9 resulted
in diminished cervical sensitivity to N-9 application rela-
tive to the initial exposure and (ii) cytokine release and
CD14-positive cell infiltration subsequent to N-9 expo-
sure varied with the number of exposures. These studies
provide new insights into the mechanisms underlying the
failure of N-9 as a microbicide and suggest a new parame-
ter for assessing future microbicide candidate molecules.
Methods
Animals
Five- to six-week-old female outbred Swiss-Webster
mice (CFWW) were utilized for all experiments (Charles
River Laboratories International, Inc., Wilmington, MA).
Mice were synchronized 7 and 3 days prior to the start
of each experiment with a 0.2 mL subcutaneous injection
of Depo-ProveraW (Pharmacia and Upjohn Company) di-
luted in Lactated Ringer’s Solution (Baxter) for a final dose
of 3 mg/animal. Prior to intravaginal application, mice
were anesthetized with a formulation of ketamine/xylazine
(100–200 mg/kg and 5–10 ng/kg, respectively). Anesthe-
tized animals then received a single intravaginal inocu-
lation (60 μL) of saline or N-9 diluted in saline. Mice
treated with saline alone were included as controls at all
time points to evaluate the normal tissue morphology in
the cervicovaginal mucosa. After treatment, mice were
humanely sacrificed and the cervicovaginal tracts were
surgically excised and prepared for histological exami-
nation. Each experiment evaluated three animals at each
time point within each test group. All animal studies con-
formed to the “Guiding Principle in the Care and Use of
Animals” approved by the American Physiological Society,
and were approved by The Drexel University College of
Medicine Institutional Animal Care and Use Committee
(IACUC).
Multiple exposure experiments
The previously described single application protocol
[23,25] was adapted to investigate the effects of multi-
ple N-9 exposures. In the first set of experiments, four
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to the mice. This protocol parallels the FDA standardized
rabbit vaginal irritation (RVI) study design, which utilizes
10 consecutive daily applications. Unlike the RVI protocol,
however, the present experimental design also included
intermediate assessments of tissue damage at acute post-
application time points. Specifically, animals were sacri-
ficed at acute exposure durations of 10 min, 2 h, and 4 h,
and at longer exposure times of 8 h and 24 h following
each application for additional and more stringent assess-
ments of cervicovaginal toxicity (Figure 1A). These acute
exposure durations were previously used to characterize
the onset and development of epithelial damage follo-
wing single microbicide application [23,25]. In addition,
these exposure durations are presumed to be within a
likely window of STD pathogen exposure and infection.
The longer exposure durations have been shown to beFigure 1 (A) Multiple exposure experimental timeline and
cervicovaginal tissue exposure controls. Female Swiss Webster
mice were exposed to N-9 daily for four days, resulting in four
experimental groups of mice. Within each exposure group, subsets
of mice were sacrificed at 10 min, 2 h, 4 h, or 8 h after exposure.
(B-E) One mouse was exposed to saline and sacrificed after each
post-exposure period. Photo micrographs (40× magnification) of
representative tissues from the 2 h time point are shown. Vaginal
(B, D) and cervical (C, E) epithelial tissues were examined for
damage after a single exposure (B, C) or after 4 exposures (D, E) to
saline. The tissue damage score (see also Table 1) is shown in the
lower right corner of each panel.important for characterizing the time course of epithelial
repair and subsequent tissue inflammation.
Prior to excision of the reproductive tracts, animals
were vaginally lavaged using 150 μl Lactated Ringer’s So-
lution (Baxter) by reverse pipetting. Lavage fluids were
collected and stored at −80°C prior to analyses of cyto-
kine content. The cervicovaginal tract was then excised,
formalin-fixed, and embedded in paraffin using standard
procedures. Tissue sections set aside for further proces-
sing were chosen to show epithelial tissues from the lo-
wer vaginal tract and the cervix. Sections were stained
with hematoxylin and eosin (H&E) for assessment of tis-
sue damage; representative fields from each treatment
group were imaged and documented using deconvolu-
tion microscopy.
Measurement of cytokine levels in vaginal lavage fluids
Cytokine levels in collected vaginal lavages were mea-
sured using a Luminex 100/200 instrument (Luminex
Corporation, Austin, TX). Two murine pro-inflammatory
cytokines – interleukin-1β (IL-1β) and interleukin-6 (IL-6)
– were measured using commercially available plates
(Millipore). Lavage samples were thawed on ice and then
centrifuged for 5 minutes at a high speed to pellet any
debris or mucus and to prevent plate filter clogging. Sam-
ples (25 μL per well) were added to the plate in duplicate
and processed as described by the manufacturer. Results
were analyzed using Xponent 3.1 software (Luminex) and
graphed using Microsoft Excel to visualize changes in
cytokine levels.
Immunohistochemical staining for immune cell
localization
Paraffin-embedded tissue sections were deparaffinized and
rehydrated using xylene, an ethanol gradient, and deio-
nized water as per standard protocol. Antigen retrieval
was performed using trypsin in a humidified chamber fol-
lowed by steaming while treating tissue with target re-
trieval solution (Dako S1700) for 30 min. Following this
incubation, the tissue sections were treated with hydrogen
peroxide and then blocked with R.T.U. normal horse
serum (Vector). Primary anti-CD14 antibody (Abcam)
was applied at a 1:500 dilution followed by the secondary
antibody (ImmPRESS Reagent Kit peroxidase, Vector MP-
7401). After the incubation with the secondary antibody,
visualization of the cells was performed using the DAB:
Peroxidase Substrate Kit (Vector SK-4100). The tissue was
then counterstained using hematoxylin (Vector H3401)
and was processed through an alcohol gradient and xylene
before application of a coverslip mounted using cytoseal
XYL mounting media (Richard Allan Scientific 8312–4).
Staining was performed by Paragon Bioservices. Levels of
staining were assessed qualitatively in sections prepared
from three mice at each time point.
Table 1 Scoring system used for the assessment of
cervicovaginal epithelial tissue damage subsequent to
N-9 exposure
Score Description of epithelial damage
0 No epithelial disturbances or sloughing of epithelial cells
1 Light epithelial damage and disruption – localized loss of tissue
integrity and epithelial sloughing over less than 5% of the
epithelial surface, which is otherwise contiguous and intact
2 Moderate epithelial damage and disruption – Multiple areas of
epithelial disturbance representing 5-25% of the total epithelial
surface and small regions of sloughing that expose the basal cell
layer
3 Severe epithelial damage and disruption – Sloughing over large
sections of the epithelial surface (> 25%) that exposes the basal
cell layer
Figure 2 After a single exposure to N-9, severe toxicity was
observed in the cervix. Mice were exposed once to unformulated
N-9 at a concentration of 1% for the indicated durations. H&E-
stained tissue sections (shown at 40× magnification) were assessed
for vaginal (A, C, E, G) and cervical (B, D, F, H) epithelial toxicity and
scored. The tissue damage score (see also Table 1) is shown in the
lower right corner of each panel.
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Toxicity after a single N-9 exposure is localized to the
cervix
The importance of assessing the impact of multiple ex-
posures of N-9 on epithelial integrity and inflammation
was illustrated by the negative consequences of frequent
N-9 exposures reported in clinical trials [20,26]. To de-
termine if multiple applications of N-9 affected cer-
vicovaginal tissue sensitivity and subsequent recovery
rates of the damaged epithelium, Swiss Webster mice
were treated with 1% unformulated N-9 once daily for 4
consecutive days. Following each application, a subset of
mice was sacrificed and cervicovaginal tissues were har-
vested 10 min, 2 h, 4 h, and 8 h after each application
and assessed for morphological damage (Figure 1A). The
tissues were scored visually according to a four-point tis-
sue scoring system (Table 1).
In control animals, saline application caused no damage
to the cervicovaginal epithelium. At 2 h post-exposure,
the vaginal (Figure 1B) and cervical (Figure 1C) epithelia
were unaffected by a single exposure to saline. Simi-
larly, no damage to the vaginal (Figure 1D) or cervical
(Figure 1E) epithelia was apparent after four daily expo-
sures to saline. Similar results were obtained at days 2 and
3, and after post-exposure durations shorter (10 min) or
longer (4 h and 8 h) than 2 h (data not shown). Saline
controls were considered representative of healthy tissue,
since mock-exposed tissues and saline-exposed tissues
were indistinguishable (data not shown).
A single exposure to N-9 also had a minimal effect on
vaginal epithelial integrity. There was little to no damage
to the vaginal epithelium detectable 10 min after a single
exposure to 1% N-9 (Figure 2A), despite the concurrent
appearance of moderate to severe damage in the cervix
(Figure 2B). Although some indications of toxicity were
apparent in the upper layers of the vaginal epithelium
at 2 h post-exposure, this damage was very limited; the
majority of the lower vaginal epithelium appeared to be
intact (Figure 2C). At 4 h post-application, the vaginalepithelium appeared to be unaffected by N-9 exposure
(Figure 2E). At 8 h following the single application of
N-9, light tissue sloughing was observed in the vagina
(Figure 2G).
In sharp contrast, damage to the cervix was readily ap-
parent by 10 min after a single application of N-9
(Figure 2B), with swelling of cells in the columnar epi-
thelium, sloughing of the superficial layers of the epithe-
lium, and presumed apoptosis. Severe sloughing across
most of the superficial epithelium (leaving the basal layer
intact) was consistently observed in the cervix 2 h post-
application (Figure 2D). By 4 h post-exposure, there was
scant superficial epithelium remaining with some foci
showing complete epithelial denudation (Figure 2F). At
8 h post-exposure, very little of the superficial columnar
cell layer of the cervical epithelium remained, leaving
large areas of the deeper basal cell layer almost
Figure 3 Cervical epithelial damage is still apparent after two
daily exposures to N-9. Mice were exposed twice to unformulated
1% N-9 and sacrificed after the indicated post-exposure intervals
following the second exposure. H&E-stained tissue sections (shown
at 40x magnification) were assessed for vaginal (A, C, E, G) and
cervical (B, D, F, H) epithelial toxicity and scored. The tissue damage
score (see also Table 1) is shown in the lower right corner of
each panel.
Figure 4 Cervical epithelial damage is still apparent after three
daily exposures to N-9. Mice were exposed once daily over three
days to unformulated 1% N-9 and sacrificed after the indicated post-
exposure intervals following the third exposure. H&E-stained tissue
sections (shown at 40× magnification) were assessed for vaginal
(A, C, E, G) and cervical (B, D, F, H) epithelial toxicity and scored. The
tissue damage score (see also Table 1) is shown in the lower right
corner of each panel.
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tained only one or two layers of basal cells with larger
areas of complete epithelial denudation (Figure 2H). By
24 h after N-9 application, however, the cervical epithe-
lium more closely resembled saline-exposed tissue, sug-
gesting a process of tissue repair during the preceding
16 hours (data not shown).
Cervical sensitivity to N-9 exposure decreases with
increasing exposure number
Assessments of tissue damage after the second exposure
to N-9 continued to reveal minimal damage to the vaginal
tissue and considerable toxicity in the cervix (Figure 3).
Damage to the vagina after the second exposure was limi-
ted and isolated to the upper layers of the vaginal epithe-
lium at 2 h post-exposure (Figure 3C). At 4 h after the
second application, however, the majority of the vaginalepithelium appeared to have a more compact histological
presentation (Figure 3E). Although the integrity of the
continuous epithelial barrier remained intact, the cell
morphology appeared denser and more tightly connected.
Damage to the cervix at 10 min and 2 h post-exposure
was moderate, but less severe than after the first exposure
(Figure 3B and D). However, moderate shedding of the
epithelial layer was evident and occasional breaks in the
epithelial lining, which exposed the lamina propria, were
observed. Cervical epithelial repair was again evident by
24 h post-application (data not shown).
After the third N-9 exposure (Figure 4), the vaginal
epithelium again appeared more compact and thinner
(relative to saline-exposed tissue), especially on the lower
layers of the stratified squamous epithelium. The cellular
structure of the upper stratified layers appeared to have a
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the process of being shed. However, the vaginal tissues were
still continuous and intact, with no breaks in the tissue.
Damage to the cervix after the third exposure was less at
10 min (Figure 4B) and 2 h post-exposure (Figure 4D) rela-
tive to the damage observed after like durations on day 2.
Following the fourth exposure, N-9 toxicity was evident
again predominantly in the cervix (Figure 5). The vaginal
epithelium was generally intact, with minimal cellular
shedding in the upper layers of the mucosa at 10 min and
2 h post-application (Figure 5A and C). The lower layers
of stratified squamous epithelium still exhibited a more
compact appearance. However, tissues analyzed at 4 h and
8 h post-exposure were more similar to the control tissues
(Figure 5E and G). As was observed on day 3, the cervical
epithelium appeared to be more tolerant to N-9 exposureFigure 5 Cervical epithelial damage after four exposures to
N-9 is considerably less relative to the damage caused by a
single exposure. Mice were exposed once daily for four days to
unformulated 1% N-9 and sacrificed after the indicated post-
exposure intervals following the fourth exposure. H&E-stained tissue
sections (shown at 40× magnification) were assessed for vaginal
(A, C, E, G) and cervical (B, D, F, H) epithelial toxicity and scored. The
tissue damage score (see also Table 1) is shown in the lower right
corner of each panel.after the fourth application relative to cervical epithelial
tissues exposed once (day 1) or twice (day 2). With each
daily exposure, the morphology of the cervix changed to a
more compact structure, and appeared as a multi-layered
structure at all time points after the fourth N-9 application
(Figure 5B, D, F, and H). After the fourth application of
1% N-9, mucous-producing cells were absent in more
than 50% of the N-9-exposed mice despite the recovery of
the endocervical epithelium and reconstruction of an in-
tact epithelial barrier over the lamina propria. This obser-
vation suggests the absence of normal mucous secretion.
When tissue sections from the cervix were scored with re-
spect to the degree of epithelial damage (Table 1), cervical
epithelial damage scores at all four time points after the
fourth daily exposure were significantly lower than corres-
ponding damage scores recorded after the initial exposure
on Day 1 (Table 2).
Pro-inflammatory cytokine release varies after multiple
N-9 exposures
Cervicovaginal lavages were also collected during the mul-
tiple exposure experiments to assess the release of cyto-
kines subsequent to single or multiple exposures to N-9.
We hypothesized that comparisons of pro-inflammatory
cytokines released on days 1 and 4 would reveal notable
differences, given the considerable and significant his-
tological differences between cervical tissues subjected to
one or four daily exposures to N-9. Because previous
in vitro, rabbit, and human studies identified IL-1β and
IL-6 as significant predictors of cervicovaginal toxicity fol-
lowing single or multiple exposures to N-9 [27,28], the
present studies were focused on these factors.
Analyses of IL-1β release demonstrated that the first
exposure to N-9 caused a small but steady increase in
IL-1β protein release into the cervicovaginal lumen, with
concentrations peaking at approximately ~10 pg/ml at
24 h post-exposure (Figure 6A). In contrast, IL-1β con-
centrations after the fourth N-9 exposure (Figure 6B)
rapidly increased from baseline to ~115 pg/ml at 10 min
post-exposure but returned to pre-exposure levels by 2 h.Table 2 Average damage scores for cervical epithelial
tissues exposed to N-9
N-9 exposure duration
10 min 2 h 4 h 8 h
Exposure 1/Day 1 1.3 ± 0.3 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0
Exposure 4/Day 4 0.0 ± 0.0 1.0 ± 0.0 1.7 ± 0.3 0.7 ± 0.3
P value, Day 1 vs. Day 4 0.016 <0.0001 0.016 0.002
After the first or the fourth daily exposure to N-9, mice were sacrificed following
the indicated post-exposure intervals. Scores (as described in Table 1) were
assigned to cervical tissue sections after multiple fields from three replicate mice
at each time point within each exposure group were examined microscopically.
Each value is expressed as an average score ± standard error. Significant
differences between scores on Days 1 and 4 are indicated by p values less than
0.05 (as calculated by an unpaired Student’s t-test).
Figure 6 IL-1β and IL-6 are differentially released following single and multiple exposures to N-9. Female Swiss Webster mice were
exposed once or once daily over 4 days to unformulated 1% N-9 and sacrificed after the indicated post-exposure intervals following the last
exposure. Prior to sacrifice, saline cervicovaginal lavages were collected from the mice and analyzed for the presence of IL-1β (A, B) or IL-6 (C, D)
using Luminex technology. The absence of a bar indicates no detectable cytokine release over background levels. Error bars indicate standard
deviations on replicate data points.
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24 h post-exposure. Interestingly, the levels of IL-1β re-
lease did not appear to correspond with the severity of
cervical epithelial damage. Despite the appearance of
moderate to severe damage between 10 min and 8 h post-
exposure on day 1, increases in IL-1β were minimal. Con-
versely, the minimal cervical epithelial damage following
the fourth exposure was accompanied by a large but tran-
sient increase in IL-1β release.
In contrast, IL-6 levels were consistent with the degree
of cervical epithelial damage. On day 1 (Figure 6C), IL-6
release was first detected at 2 h post-exposure and
peaked at 4 h (~130 pg/ml) before returning to baseline
levels. After four daily N-9 applications (Figure 6D), IL-6
release was detected only at 2 h post-exposure at a con-
siderably lower concentration (~50 pg/ml) relative to day
1. Both IL-6 release patterns paralleled the time course
and severity of N-9-associated cervical epithelial damage.
On day 1, the peak of IL-6 release corresponded with the
severe damage to the cervical epithelia noted at 2–4 h
post-exposure. On day 4, the comparatively lower level of
IL-6 release was consistent with the reduced severity of
epithelial damage and apparent tolerance to N-9 exposure,
and coincided with the modest increase in epithelial da-
mage observed at 4 h post-exposure.CD14+ cell infiltration in the cervix increases following a
single N-9 exposure but declines after repeated daily
exposures
Previous studies of N-9 toxicity in the mouse revealed
intense infiltration of CD45-positive immune cells and
Ly6-positive neutrophils subsequent to a 2 h exposure to
unformulated N-9 [19,25]. In preliminary experiments
designed to expand these findings, mice were given a sin-
gle application of unformulated 1% N-9 and sacrificed at
2, 4, or 24 h post-exposure. Cells isolated from excised
cervicovaginal tissues before or after N-9 exposure were
analyzed by flow cytometry to identify the following
immune cell populations: CD4+/CD3+ T lymphocytes,
CD8+/CD3+ T lymphocytes, Ly6G + neutrophils, and
CD14+/CD11C- monocytes/macrophages. In addition to
the abundance of infiltrating neutrophils following N-9
exposure, these experiments indicated a 50% increase in
the number of CD14+/CD11c- cells at 2 h post-exposure
(data not shown). In addition, monocyte/macrophage
infiltration appeared to decrease by 4 h post-exposure
and returned to control levels by 24 h post-exposure
(data not shown).
To localize macrophage/monocyte infiltration following
single or multiple exposures to N-9 within the cervicova-
ginal epithelium and to confirm the preliminary findings,
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exposed tissues in conjunction with a CD14-specific anti-
body. Analyses of control tissues exposed once to saline
revealed little infiltration by CD14+ cell populations into
the vaginal (Figure 7A) or cervical (Figure 7B) epithelium.
In contrast, tissues excised at 2 h post-exposure following
a single N-9 exposure (day 1) were characterized by light
infiltration into the vaginal epithelium (Figure 7C) and in-
tense CD14 staining under the epithelial surface in the
cervix (Figure 7D). Levels of CD14+ cell infiltration in the
cervix were less at 4 h post-exposure and declined consid-
erably at 24 h post-exposure (data not shown). These
results indicated that CD14+ cell infiltration was concur-
rent with peak N-9-associated physical damage within the
cervical epithelium after a single exposure.
Because peak cervical epithelial damage after four dai-
ly N-9 exposures was observed at 4 h post-exposure
(Figure 5 and Table 2), similar analyses were performed
on cervicovaginal tissues collected at 4 h post-exposure
from mice after four daily N-9 applications. As was ob-
served after a single N-9 exposure, few CD14+ cells wereFigure 7 N-9 exposure results in CD14+ cell infiltration on day
1 and, to a lesser extent, on day 4. Female Swiss Webster mice
were exposed once to saline (A, B), once to unformulated 1% N-9
(C, D), or once daily to N-9 for four days (E, F). Mice were sacrificed
after the indicated post-exposure intervals following the last exposure.
Cervicovaginal tissue sections were stained immunohistochemically
for the CD14 cell surface marker. Representative vaginal (A, C, E) and
cervical (B, D, F) epithelial tissue sections are shown.observed in the day 4 vaginal epithelium (Figure 7E). In
the cervical epithelium (Figure 7F), CD14+ cells were pre-
sent in greater numbers relative to cell numbers in the
corresponding vaginal tissues. However, cell infiltration
was clearly not as intense as was noted at 2 h on day 1.
Furthermore, the intense cervical sub-surface staining
seen on day 1 was not apparent on day 4; infiltrating
CD14+ cells were only present deeper in the lamina
propria. CD14+ cell staining in the cervix at 4 h and
24 h post-exposure was also reduced relative to levels
noted in cervical tissues on day 1 (data not shown).
These results again indicate a parallel between physical
epithelial damage and CD14+ cell infiltration within the
cervix; apparent tolerance to N-9 exposure was accom-
panied by considerably lower levels of monocyte/macro-
phage infiltration.
Discussion
Early efforts to develop a safe and effective microbicide
ended with the observation that N-9, which had been used
safely as a spermicidal agent for over four decades [9], was
not only clinically ineffective against HIV-1 transmission,
but was also capable of significantly increasing the risk of
HIV-1 acquisition after repeated use [5]. These clinical
trial results prompted a reassessment of mechanisms of
N-9 toxicity and a general realization that a greater em-
phasis on pre-clinical microbicide safety was necessary.
One conclusion from post-failure analyses of N-9 mi-
crobicide development was that toxicity studies using
the standard rabbit vaginal irritation (RVI) model pro-
vided an incomplete picture of the adverse effects of N-9
on the cervicovaginal epithelial tissues and the relevance
of those effects to the risk of HIV-1 transmission. While
the RVI model has provided important information
regarding the safety of N-9 and other topical vaginal mi-
crobicides, there are limitations to the standard protocol.
First, despite its demonstrated sensitivity to toxic topical
agents, the RVI model does not assess product safe-
ty during the window of likely HIV-1 transmission. The
standard RVI test protocol includes only one assessment
of toxicity at 24 h after the final product application and
does not provide for measures of toxicity at more acute
post-exposure intervals, particularly the first hours after
topical application when sexual intercourse and HIV-1
transmission are likely to occur. Our previous studies
using the mouse model of cervicovaginal toxicity de-
monstrated that N-9- and C31G-mediated damage was
greatest at 2 to 4 h post-exposure and was minimal or
undetectable by 24 h post-application [19,24,25], presu-
mably because epithelial repair mechanisms had restored
the epithelium to its pre-exposure state. The standard RVI
model would not reveal these important milestones in the
time course of N-9 topical toxicity. Second, this model
also differs from the human female reproductive tract
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reproductive stages, (ii) is not colonized by lactobacillus
(resulting in a lack of acidity within the vaginal tract), (iii)
lacks the production of cervicovaginal mucus, and (iv) is
characterized by a columnar epithelium in the upper va-
gina (cervicovagina) and a stratified squamous epithelium
in the lower vagina (urovagina) [29-32].
We developed a Swiss Webster murine model [19] to
assess cervicovaginal tissue integrity and inflammation fol-
lowing exposure to candidate vaginal microbicides and to
specifically address the need for an in vivo model system
that can be used to provide pre-clinical results predictive
of clinical trial outcomes. The Swiss Webster mouse is a
readily accessible, outbred stock strain that has previously
been used as a model for studies of various infectious cer-
vicovaginal tract pathogens, including Chlamydia tracho-
matis, herpes simplex virus, and group B streptococci
(GBS). These mice have also been used in various pre-
clinical microbicide studies [33-37]. The Swiss Webster
mouse model offers several distinct advantages over the
RVI model and other approaches used for the evaluation
of cervicovaginal toxicity and inflammation associated
with exposure to topical microbicides. First, the Swiss
Webster mouse is a relatively inexpensive animal model,
permitting large, pre-clinical toxicity screens of candidate
compounds under a variety of experimental conditions
(including multiple exposure protocols) that can be used
to evaluate cervicovaginal toxicity and inflammation at
the cellular and tissue level prior to Phase I safety trials.
Second, previously published observations from experi-
ments involving this model [19,25] have indicated close
parallels to clinical findings, demonstrating the value of
this model as a prescreening tool to prevent costly and
time-consuming clinical trials on compounds with un-
acceptable safety profiles. Third, the mouse model, unlike
the RVI model system, can be used to assess regional dif-
ferences in cervicovaginal toxicity. This is an important
feature of this animal model system, since topical toxicity
can be tissue-specific, as we have demonstrated in past
studies [19,25,38]. Consideration of regional differences in
FRT toxicity may be relevant to understanding mechan-
isms of HIV-1 transmission, since non-human primate
studies of SIV cervicovaginal infection suggest that HIV-1
transmission within the FRT may be regionally con-
strained [39,40], perhaps by the nature of the epithe-
lial barrier or by regional differences in the distribution of
HIV-1-susceptible immune cell populations [41]. The mo-
del, however, is not without its limitations: the lack of co-
lonizing lactobacillus (addressed only in the non-human
primate model); a higher cervicovaginal pH relative to the
human FRT; and the use of Depo-Provera to pretreat the
animals prior to experimentation.
The present studies, through the single N-9 exposure
aspect of these experiments, have confirmed observationsreported in previously published studies [19,25]. First, the
cervical epithelium is severely damaged by a single expo-
sure to N-9, while the vaginal epithelium remains rela-
tively intact. The damage to the cervical epithelium is
characterized by breaks in the columnar tissue architec-
ture and severe tissue sloughing. Second, N-9-associated
cervical epithelial damage occurs relatively rapidly. After a
single exposure to 1% N-9, the damage to the cervical
epithelium was greatest at 2 to 4 h post-exposure. Third,
physical damage can be accompanied by intense immune
cell infiltration. Unlike the present studies, past experi-
ments identified the infiltrating cells as positive for CD45,
which is a pan-leukocyte cell surface marker. Finally, the
damage caused by a single N-9 exposure is transient and re-
solved over a period of approximately 24 h post-exposure.
The single exposure results also suggest that tissue da-
mage may not be strictly associated with the anatomy of
the cervicovaginal tract. We consistently observed severe
N-9-associated damage to the columnar epithelium of the
cervix and minimal damage to the stratified squamous
epithelium of the lower vagina. However, one of the vagi-
nal sections (Figure 3C, Day 2/Exposure 2, 2 h) shows in-
tact stratified squamous epithelium adjacent to damaged
columnar epithelium (roughly the lower half of the field),
which is presumed to be part of the upper vaginal tract.
Under Depo-Provera pre-treatment, the upper vaginal
tract assumes a morphology typified by a single layer of
columnar cells overlying 1–2 layers of basal cells. These
observations indicate that epithelial damage subsequent to
N-9 application is dependent on the architecture of the
epithelial tissue rather than its anatomical location, and
that a columnar epithelium, regardless of its location, is
more susceptible to N-9 toxicity than a stratified squa-
mous epithelium.
The present studies also provide new information re-
garding N-9 toxicity that is relevant to increases in HIV-1
transmission after repeated exposure to N-9. During re-
peated daily exposures to unformulated 1% N-9, the cer-
vical epithelium appeared to become less sensitive to the
degradative effects of N-9 application. By the fourth appli-
cation, the damage caused by N-9 application was less and
the peak damage was observed at 4 h post-exposure rather
than at 2 h post-exposure as seen following the first appli-
cation of N-9. This observation suggests the possibility
that changes in the epithelial architecture after the initial
exposure, insult, inflammation, and repair provide a pro-
tective mechanism against the effects of subsequent N-9
exposure.
This apparent tolerance to N-9 exposure after multiple
applications may likely be related to changes in cervical
tissue morphology observed during these studies. After
multiple N-9 exposures, the tissue appeared to be meta-
plastic, forming multiple layers of stratified squamous
epithelium instead of the usual single layer of columnar
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lium. This effect has been observed subsequent to stress
applied to tissue over time [42]. The increased tolerance
of this metaplastic tissue is consistent with the above
conclusion that susceptibility to N-9-associated damage
is dependent on tissue architecture rather than anatom-
ical location, since the stratified cervical tissue observed
in day 4 mice was more tolerant of N-9 exposure com-
pared to the columnar cervical epithelial tissue found in
day 1 mice. One focus of future studies will be to deter-
mine the amount of time required for repaired and to-
lerant tissues to return to their baseline structures and
levels of susceptibility to damage.
The present studies also revealed new information about
relationships between repeated N-9-associated damage
and induced tissue inflammation. Following N-9 exposure,
the release of the pro-inflammatory cytokines IL-1β and
IL-6 was detected in vaginal lavages, reinforcing the roles
for these cytokines as important mediators of the inflam-
matory response in the vaginal tract in response to mi-
crobicide application [27,28]. However, only IL-6 release
coincided with cervical epithelial damage (2–4 h post-
exposure) after the initial N-9 application. In contrast,
minimal amounts of IL-1β were detected on day 1. Con-
versely, IL-1β was released quickly (10 min post-exposure)
and in relatively large amounts on day 4 relative to day 1.
While IL-6 release was also detected on day 4, the magni-
tude of release was considerably less. In all cases, cytokine
increases were transient and returned to control levels by
8 to 24 h post-exposure as tissue regeneration was in pro-
gress. Although the significance of these observations has
not yet been determined, the pattern of cytokine release
suggests an association with tissue regeneration following
multiple N-9 exposures and the development of tolerance
to N-9 application.
Subsequent to N-9 exposure, CD14+ monocytes/ma-
crophages were also detected as part of the immune cell
infiltrate. The intense, sub-surface presence of CD14+ im-
mune cells after the first exposure to N-9 coincided with
the cervical localization of epithelial damage, the peak se-
verity of damage at 2 to 4 h post-exposure, and the detec-
tion of IL-6 in the vaginal lavage. The association between
IL-6 release and the presence of CD14+ immune cells sug-
gests that the source of the IL-6 may be the monocyte/
macrophage population within the infiltrate [43,44]. This
hypothesis is also consistent with the concomitant de-
crease in CD14+ cells and reduction in released IL-6
at 8 and 24 h post-exposure, and with the association
between the reduced levels of IL-6 and lower numbers of
infiltrating CD14+ cells on day 4.
Conclusions
These studies provide new insights and raise new ques-
tions about cervicovaginal damage associated with multipleexposures to topical agents with epithelial toxicity. Future
studies will need to explore several aspects of these results,
including the underlying mechanisms of cervicovaginal
epithelial regeneration and tolerance to toxic agents, and
the involvement of the inflammatory response in the pro-
cess of tissue recovery. Additional experiments will need to
examine the effects of multiple exposures to toxic agents
such as N-9 during a single day, since increases in the risk
of HIV-1 acquisition were attributed to multiple uses of
N-9 within a single 24 h period [5]. Finally and most im-
portantly, these studies suggest the need for multiple ex-
posure protocols in future safety and efficacy assessments
during the pre-clinical development of topical vaginal (and
rectal) microbicides effective against HIV-1 transmission.
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